Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
New England Journal of Medicine2005Vol. 352(22), pp. 2285–2293
Citations Over TimeTop 1% of 2005 papers
Mark J. Rieder, Alexander P. Reiner, Brian F. Gage, Deborah A. Nickerson, Charles S. Eby, Howard L. McLeod, David K. Blough, Kenneth E. Thummel, David L. Veenstra, Allan E. Rettie
Abstract
VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. The molecular mechanism of this warfarin dose response appears to be regulated at the transcriptional level.
Related Papers
- → CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects(2011)29 cited
- Warfarin Therapy and VKORC1 and CYP Genotype(2018)
- → Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery(2015)8 cited
- → CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement(2012)4 cited
- Investigation of the Relationship between the Individual Warfarin Dosing and the Pharmacogenomics(2015)